Title: APPARATUS FOR PREVENTING VASCULAR GRAFT INTIMAL HYPERPLASIA

Abstract: To prevent intimal hyperplasia within a vascular graft (18), e.g., a dialysis graft, a flexible tube which forms the vascular graft is coated internally before placement with an anticarcinogen or mitosis-inhibiting agent for preventing cell division. The graft (18) can also be irradiated with light energy by directing light into the lumen of the tube that has been grafted in place, thereby preventing or reducing graft intimal hyperplasia and reducing inflammation. The light source (30) can be a light emitting diode (LED) or a chemical light source, i.e., a cheliluminescent substance for producing cool light energy within the graft to prevent or reduce the symptoms of graft intimal hyperplasia (GH). When phototherapy is used, the body is exposed to light radiation at the site of the graft in sufficient amount to prevent undesired cell proliferation within the vessels, the graft, or surrounding tissue where the invention is used without detectable damage to body tissue. For various applications, visible light can be used, e.g., visible blue or red light or the combination is employed.
APPARATUS FOR PREVENTING VASCULAR GRAFT INTIMAL HYPERPLASIA

FIELD OF THE INVENTION

The present invention relates to the medical arts and more particularly to the prevention of intimal hyperplasia.

BACKGROUND OF THE INVENTION

When an artificial blood vessel, i.e., a graft, is connected between an artery and a vein to act as a shunt, a tubular polytetrafluoroethylene graft is commonly used. However, many patients with a graft of this kind develop vascular graft intimal hyperplasia (GIH), a condition in which cells lining the vessels grow at a high rate thereby blocking the vessel. Although efforts have been made to reduce or eliminate hyperplasia of the graft, none of the proposed solutions have been entirely satisfactory.

Various attempts have been made to address this problem. For example, U.S. patents 5,658,894; 5,786,326; 5,874,419; 6,136,798; 5,935,940; 5,902,799; 6,605,115; 6,689,803 and 6,726,923 describe drugs, biologicals and other pharmaceutical preparations that can be used for treating intimal hyperplasia, but these substances must be taken internally or applied to the occluded vessel. Consequently, these treatments have the potential for producing an allergic reaction, side effects, or anomalous results. Other approaches have been taken, for example, U.S. patent 6,669,260, describes an invasive procedure in which the occlusion is surgically aspirated from the vessel. Surgical procedures are characteristically more costly, require greater expertise and may have to be repeated periodically. The methods of treatment described in the patents are therefore not entirely satisfactory.
Consequently, the need still exists for a more effective system for treating intimal hyperplasia.

In view of these and other shortcomings of the prior art, it is one objective of the present invention to provide a new apparatus for preventing vascular graft intimal hyperplasia which is well tolerated by the patient and which does not cause discernable damage to surrounding body tissue.

Another object of the invention is to provide a new apparatus of the type described which can be readily produced at a reasonable cost and is suited for wide scale use and distribution.

Another objective of the invention is to provide a new apparatus of the type described which can be implanted effectively while a surgical procedure is being performed, typically, in about 1-2 hours.

Yet another objective of the invention is to provide a new apparatus of the type described which can be provided in a compact package that is small enough to be attached to or carried by the patient without undue discomfort or inconvenience.

These and other more detailed and specific objects of the present invention will be better understood by reference to the following figures and detailed description which illustrate by way of example but a few of the various forms of the invention within the scope of the appended claims.

**SUMMARY OF THE INVENTION**

In certain surgical procedures, such as placement of a hemodialysis shunt, an artificial blood vessel is grafted between an artery and a vein to provide access to the circulatory system. This vascular graft normally consists of a plastic tube or the like, e.g., a polytetrafluoroethylene tube is typically used. Briefly, to prevent intimal
hyperplasia within and proximate to the plastic tube in accordance with the present
invention, the flexible plastic tube is prepared by coating the tube interiorly before
placement with an agent for preventing cell division, e.g., an anticarcinogen or other
mitosis inhibiting drug to be described in more detail below for preventing cell
division or growth. The graft can also be radiated with light energy or light energy can
be used alone so as to direct light into the interior of the tubular shunt for reducing
inflammation and preventing or reducing dialysis graft intimal hyperplasia. The light
source can, for example, be a light emitting diode (LED) or a chemical light source,
_i.e._, a chemiluminescent substance for transmitting cool light energy into body tissue
to prevent or reduce the symptoms of GIH. In accordance with the invention, the graft
is exposed to light radiation in a sufficient amount to prevent undesired cell
proliferation within the vessels, graft and surrounding tissue without detectable
damage to body tissue. In one preferred form of the invention, visible blue or red light
or the combination of them is employed. Blue and red light can be provided by an
incandescent lamp or other suitable lamp, an LED, a laser or chemical light source
with preferred wavelengths predominantly between about 300 nm to about 800 nm.

**BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 is a side elevational view showing a dialysis graft according to the
invention placed on the forearm of the patient.

Figure 2 is a cross-sectional view on a larger scale taken on line 2-2 of Fig. 1.

Figure 3 is an elevational view partly in section of the light irradiation unit
shown in Figure 1 on a larger scale.

Figure 4 is a cross-sectional view taken on line 4-4 of Figure 3 on a slightly
larger scale.
DETAILED DESCRIPTION OF THE INVENTION

The present invention provides an apparatus for the avoidance and treatment of vascular intimal hyperplasia and is especially well suited for use in hemodialysis grafts or access. Dialysis graft intimal hyperplasia (GIH) occurs in a large segment of the hemodialysis (HD) population and is the cause of significant cost, morbidity and mortality in the HD population. Greater than 50% of HD patients in many areas have expanded polytetrafluoroethylene (PTFE) grafts.

In accordance with the present invention, the graft tubing is coated interiorly before placement with an anticarcinogen or other agent for preventing cell division or growth. Thus, intimal hyperplasia, brought about by various growth factors, is inhibited in accordance with the invention by an agent for inhibiting cell division, e.g., drugs such as, but not limited to, sirolimus as well as other agents for controlling cell division as described more fully below. The graft can also be provided with a source of light energy arranged to direct light onto the graft tubing for reducing inflammation and thereby preventing GIH. Phototherapy thus prevents cell division through the application of visible light and similar modalities at the time of engraftment or during angioplasty of the stenotic area in treating intimal hyperplasia and graft stenosis.

Many dialysis patients undergo hemodialysis for treatment of chronic renal failure. Maintaining a patent access is of paramount importance in this group of patients. In the U.S. only approximately 50-80% of patients using a PTFE shunt have patency at two years. Because most patients have poor native vessels, artificial graft material in many instances is the mode of choice for chronic vascular access. Approximately 0.5-0.8 episodes of fistula thrombosis occur per patient year of those on dialysis. Most frequently this results from venous outflow obstruction.
Approximately 75% of all thromboses are associated with stenotic lesions in the venous system at the point of anastomosis.

Surgical thrombectomy, lytic therapy, balloon angioplasty and surgical graft replacement are the most common treatments for venous stenosis. All these are associated with great cost, morbidity and on occasion mortality. Therefore, primary prevention of venous stenosis is a major therapeutic event in the management of hemodialysis patients.

Venous stenosis is a result of multiple factors including an inflammatory response at the anastomotic site including vascular growth factors, platelet-derived growth factor, basic fibroblast growth factor and transforming growth factor. It has been shown in the use of drug-eluting coronary stents that there is mitigation of these factors, and therefore much lower restenosis rates compared to non-drug coated stents. According to the present invention, a coating comprising an agent for preventing cell growth or division is applied to and most preferably is provided within the dialysis graft material itself. The coating or agent comprises at least one anticancer drug or other agent that regulates cell proliferation and/or growth such as, but not limited to, paclitaxel, sirolimus, taxol and methotrexate to prevent cell growth and stenosis in the dialysis graft. Another cell proliferation inhibiting agent is blue light phototherapy which is used to augment and treat graft prophylactically and at the time of intervention for venous stenosis. Phototherapy applied in this manner has been demonstrated to inhibit cell growth at specific endovascular and enteric sites.

Refer now to the Figures which illustrate the invention by way of example. Shown in Figures 1 and 2 is one of the most common types of arteriovenous grafts. The forearm is indicated at 10, the upper arm at 12, the brachial artery at 14 and the basilic vein at 16. A loop graft 18 is formed from a short section of PTFE tubing
which is grafted surgically as shown to provide an arteriovenous anastomosis. The PTFE tube is used conventionally in this example as a hemodialysis graft in the treatment of kidney disease.

The graft 18 includes an inner drug eluting coating or layer 20 (Figure 2) which is impregnated with the cell growth regulator described above. The coating 20 can comprise any suitable biocompatible matrix such as a plastic resin, elastomer or hydrophilic gel. The coating 20 can, for example, be a matrix that is formed from any of the commercially available implantable compositions that are used for providing a gradual release of a medicament, \textit{e.g.}, the same composition in Norplant® implantable hormone releasing strips that are used in birth control. The drug-eluting matrix 20 can, for example, compromise a copolymer of dimethylsiloxane and methyl vinyl siloxane which is sold by Dow Corning, Inc. under the trademark Silastic®. The cell division inhibiting agent can be dispersed in the matrix 20 at a concentration of about 0.1\% to about 65\% by weight. To prevent thrombus formation, the matrix can also include an anticoagulant, \textit{e.g.}, heparin in the amount of about 0.05\% to about 10\% by weight.

Other suitable cardiovascular implant polymers include polyurethane, polyurethane/silicone copolymers (Elast-Eon® by AorTech Intl PLC), and silicone rubber. Erodible matrix polymers which are biocompatible include Vicryl®, a polylactic acid/polyglycolic acid copolymer. Other erodible bio-implantable matrix polymers include polyortho esters, poly(alpha-hydroxy ester)s, and polyanhydrides. Synthetic matrix bio-erodible polymers also include tyrosine-derived polycarbonates and polyacyrulates, lactide based polydepsipeptide polymer, poly(L-lactic acid-do-L-aspartic acid), and lactide based poly(ethylene glycol).
The matrix 20 acts as a carrier for the sustained release of the cell-growth control agent at a selected rate into the blood passing through the lumen 22 of the graft 18. The drug-filled matrix 20 can extend throughout the entire length of the loop graft 18 including the end portions which are sutured to the native blood vessels 14 and 16. As the control agent is continuously released from the inner layer 20 of the graft 18, the undesirable cell growth and stenosis in the dialysis graft that formerly occurred is either entirely eliminated or reduced to a tolerable level. Optionally, the coating 20 is also applied to the outside surface of the graft 18.

In accordance with the present invention, light energy is used with the chemotherapeutic treatment described above or by itself to reduce or eliminate hyperplasia. The light energy applied to the graft can be any suitable visible light, especially red light or blue light in the range of 300 – 500 nm peaking about 400 nm to 430 nm. When red light is used, it typically has a wavelength in the range of about 600-800 nm with a peak in the range of about 630-650 nm. A combination of blue and red light can also be used.

Light can be provided by various light sources including light emitting diodes. While suitable LED’s that are capable of producing visible light in any portion of the spectrum can be employed, wavelengths in a range of from about 300-500 nm and especially in range of about 400-430 nm are preferred. When the power supply consists of batteries, only a fraction of the watt will be produced but if an external power supply (30) is provided, the LED’s can produce several watts of power. Luminous flux that results is capable of penetrating the entire graft. Any suitable commercially available power supply 30 can be used. Current is supplied by a power cord 33 and power is controlled by switches 31.
The use of visible light is especially effective because mobile proliferating cells absorb the blue or red light energy and in the presence of oxygen, free radicals are then generated which are believed to be ultimately responsible for the death or debilitation of the proliferating cells through apoptosis, necrosis or from other causes. Red light also decreases inflammation by acting directly on the surrounding tissue.

In accordance with the present invention, light can be provided by any of several different light sources including but not limited to incandescent light sources, gas discharge tubes, light emitting diodes (LED), laser diodes, chemiluminescent sources, mercury vapor tubes and other light sources known in the art. Light emitting diodes and chemiluminescent sources are particularly useful because they are capable of producing cool light, i.e., light that does not generate sensible heat. When a chemiluminescent source is used, the light can be transmitted directly onto and within the graft as long as required to accomplish the desired treatment, typically for the length of a surgical procedure that is being performed, e.g., about 1-1.5 or 2 hours.

As shown in Figures 1 and 2, the graft 18 is provided with an outer coating 24 for producing light through photogenesis, i.e., phosphorescence or chemical light, to inhibit cell division through phototherapy for the purpose of treating the graft prophylactically as well as at the time of interventions for venous stenosis. The coating 24 can be any of the commercially available photoluminescent compounds, preferably those that produce visible light and especially light in the blue spectral range for reducing or entirely preventing undesired cell growth and stenosis in the dialysis graft. Surrounding the coating 24 is a light reflector 25 comprising an aluminized plastic film for reflecting all light radiation centrally into the lumen of the tubing 18. The luminescence provides cool light radiation that penetrates to the interior of the tubing 18 through coating 20 for preventing cell proliferation within the
graft and adjacent vessels or other tissue in the same manner described hereinabove and is allowed to provide light radiation therapy until light is no longer produced. An advantage of using a chemical or chemiluminescent liquid is that light radiation of a cool variety produces the desired therapeutic effect but since little if any heat is produced which can be sensed, there will be no damage to the surrounding tissue of the patient. A variety of chemiluminescence substances can be employed such as luminal and lucigenin. Among the preferred light producing chemicals are the oxilaic ester and hydrogen peroxide with an efficient fluorescer and catalyst as disclosed in U.S. Patent 3,597,362, which is incorporated herein by reference.

Other kinds of fluorescent compounds include: the conjugated polycyclic aromatic compounds examples of which are anthracene, benzanthracene, phenanthrene, naphthacene, pentacene, perylene, perylene violanthrone, and the like and their substituted forms.

Typical substituents for all of these are phenyl, lower alkyl (C.sub.1 - C.sub.6), chloro, bromo, cyano, alkoxy (C.sub.1 - C.sub.16), and other like substituents which do not interfere with the light-generating reaction can be used.

The preferred fluorscens include 9, 10-bis(phenylethynyl) anthracene, 1-methoxy-9, 10-bis(phenylethynyl) anthracene, perylene, 1,5-dichloro 9, 10-bis(phenylethynyl) anthracene, rubrene, monochloro and dichloro substituted 9,10-bis(phenylethynyl) anthracene, 5,12- bis(phenylethynyl) tetracene, 9,10-diphenyl anthracene, and 16,17-dihexyloxyviolanthrone.

The lifetime and intensity of the chemiluminescent light emitted can be regulated by the use of certain regulators such as: (1) by the addition of a catalyst, which changes the rate of reaction of hydroperoxide. Catalysts which accomplish that objective include those described in M. L. Bender, Chem. Revs., Vol. 60, p. 53
(1960). Catalysts can also be used which alter the rate of reaction or the rate of chemiluminescence including those accelerators of U.S. Pat. No. 3,775,366, and decelerators of U.S. Pat. Nos. 3,691,085 and 3,704,231, or (2) by the variation of hydrogen peroxide. Both the type and the concentration of hydrogen peroxide are critical for the purposes of regulation.

Of the catalysts tried, sodium salicylate and various tetraalkylammonium salicylates have been the most widely used. Lithium carboxylic acid salts, especially lithium salicylate, lithium 5-t-butyl salicylate and lithium 2-chlorobenzoate are excellent catalysts for low temperature hydrogen peroxide/oxalate ester/fluorescer chemiluminescent systems.

Chemical light can be produced by a mixture of reagents, e.g., an oxalate ester and hydrogen peroxide together in the presence of a catalyst and a fluorescer. Typically, fluorescers are chosen that are peroxide stable to provide a long lasting glow. In most instances, a single fluorescer has been used to produce a particular colored light. In some cases, two or more fluorescers of essentially equivalent stability in peroxide have been mixed to produce a blended color. As an example, a blue emitting fluorescer will be mixed with a red emitting fluorescer to make a pink light.

Of the numerous fluorescers described herein, relatively few emit light in peroxyoxalate chemiluminescence and are sufficiently peroxide stable (five phenylethynyl anthracenes, one violanthrone, and three perylene dicarboximides) to yield commercially viable products. While other fluorescers are known to emit light, they are not peroxide stable and have historically been rejected for commercial use (see patent 6,267,914). All publications and patents are herein incorporated by reference to the same extent as if each individual publication or patent was specifically and individually indicated to be incorporated by reference.
A light source comprising several light emitting diodes 26 will now be described in more detail with reference to Figures 1, 3 and 4. As shown in the Figures, the graft tubing 18 is surrounded by several light emitting diodes 26 which are connected by suitable electrical conductors 28 to the power supply 30. The diodes 26 are contained in a light reflective metal casing 27 about 1-2 cm in diameter which is secured to the graft tubing 18 at 27a and 27b. A portion of the tubing 18 within the casing 27 can be formed from glass or other transparent material 19 to enhance light transmission into the interior of tubing 18. If desired, the casing 27 can be provided with a longitudinal hinge 27c along one side to enable the casing and diodes 26 which are attached to its inside surface to be removed from the tubing whenever the need arises. When the diodes 26 are energized, they produce cool light, most preferably in the blue range of the spectrum to provide phototherapy for assisting in the treatment of the graft prophylactically or at the time of intervention so as to reduce or eliminate the symptoms of unwanted cell growth and stenosis in the hemodialysis graft. Other light sources can be used, such as incandescent light sources but are not preferred because of the heat produced. The phototherapy will thus inhibit undesired cell growth at specific endovascular and enteric sites where the light sources 24 or 26 are located as well as in the surrounding tissue into which the light penetrates. The light emitting coating 24 and the light sources 26 while shown to cover only a segment of the graft 18, can, if desired, extend the entire length of the graft including the ends that are attached to the artery 14 and vein 16.

Each light emitting diode 26 has a semiconductor chip (not shown) connected to one electrical contact and a contact wire which extends from the chip to one of the other electrical contacts. When treatment is to begin, current is supplied to the conductors 28 causing the LED’s to provide light of a selected spectral range, most
preferably blue light in the range between about 300-500 nm or red light of about 600-800 nm or a combination thereof. An important advantage of the LED's is their ability to provide cool light radiation that is highly effective in preventing hyperplasia in the graft and surrounding vessels without damaging the tissue of the patient. The LED's are turned on and allowed to remain in operation for a period of time required for effective treatment, typically 1-2 hours. If desired, the LED's can be replaced by a light emitting plastic (Lip) in which the semiconducting material is organic. Any suitable commercially available organic semiconducting material such as a PPV light emitting polymer or derivative thereof can be used. During use, the chemical composition of the PPV polymer changes with associated changes in physical and electrico-optical properties that produce light radiation. Laser diodes can be used in place of LED's if desired. It should be understood that the invention is not limited to specific apparatus or methods described and can be used with various other devices, fabrication methods, arrangements, systems and methods of employment which irradiate the graft and surrounding body tissues.

While the exact mode of operation is not known with certainty, it is believed that the phototherapeutic light radiation retards cell division of the endothelial cells that would otherwise proliferate from the areas where the graft is sutured to the vessel resulting in intimal hyperplasia of the graft. When used with the coating 20, the light energy can act synergistically by killing off cells already weakened by the cell-growth inhibiting substance in the coating 20. Thus, by preventing unwanted cell proliferation, stenosis of the graft is avoided.

The utility of the present invention in the treatment of GIH is important not only in reducing undesired cell proliferation, but also because the administration of light energy is useful in itself for reducing inflammation of the tissue. It appears that the
exposure of body tissue to light energy such as visible blue light or red light, or the combination helps to reduce inflammation of the vascular tissue in and around the graft. The present method of treatment is therefore important because a reduction in vascular inflammation *per se* can be helpful in reducing or eliminating symptoms of the disease. The reduction of inflammation as disclosed herein is also beneficial because reducing inflammation will decrease the presence of inflammatory cytokines and inflammatory chemokines. In addition, it can also reduce the presence of acute phase reactants and soluble adhesion molecule TLR4 receptor activity which is beneficial to the patient. Thus, the present invention can be used to decrease the expansion of adhesion molecules, reduce proliferation of smooth muscle cells and activate immune cells which help to reduce or eliminate the symptoms of vascular inflammatory disease.

The coatings 20 used in the invention will be better understood by reference to the following examples:

<table>
<thead>
<tr>
<th>MATRIX</th>
<th>PERCENT BY WEIGHT OF CELL GROWTH INHIBITOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrophilic Gel Matrix(^1)</td>
<td>Example 1</td>
</tr>
<tr>
<td></td>
<td>2% paclataxel</td>
</tr>
<tr>
<td></td>
<td>Example 4</td>
</tr>
<tr>
<td></td>
<td>0.5 sirolimus</td>
</tr>
<tr>
<td>Silicone Rubber(^2)</td>
<td>Example 7</td>
</tr>
<tr>
<td></td>
<td>0.2% taxol</td>
</tr>
<tr>
<td></td>
<td>Example 10</td>
</tr>
<tr>
<td></td>
<td>0.4% methotrexate</td>
</tr>
<tr>
<td>Polyurethane</td>
<td>Example 13</td>
</tr>
<tr>
<td></td>
<td>0.1% methotrexate</td>
</tr>
<tr>
<td></td>
<td>Example 16</td>
</tr>
<tr>
<td></td>
<td>1% paclataxel</td>
</tr>
</tbody>
</table>

\(^1\) Crosslinked polyethylene oxide/polyurethane copolymer 2-10% by weight, propylene glycol 2-5% by weight and water 85-96% by weight.

\(^2\) Copolymer of dimethylsiloxane and methyl vinyl siloxane.

Many variations of the present invention within the scope of the appended claims will be apparent to those skilled in the art once the principles described herein are understood.
WHAT IS CLAIMED IS:

1. A vascular graft for an animal or human patient comprising, a tube having a pair of ends adapted to be grafted to a blood vessel of the patient for circulating the patient’s blood therethrough and an agent for inhibiting cell division operatively connected to the tube so as to expose the interior of the tube to the agent for reducing or eliminating one or more of the symptoms of graft intimal hyperplasia.

2. The apparatus of claim 1 wherein the cell-division inhibiting agent comprises an anticarcinogen.

3. The apparatus of claim 1 wherein the cell-division inhibiting agent comprises a source of light energy directed onto the tube and the tube is transparent to the light energy applied thereto such that the light energy passes through the tube into the lumen thereof to thereby expose mobile proliferating cells therein to said light energy.

4. The apparatus of claim 2 wherein the agent is selected from the group consisting of paclatexel, sirolimus, taxol and methotrexate.

5. The apparatus of claim 2 wherein the agent is dispersed in a matrix comprising a member selected from the group consisting of a plastic resin, an elastomer and a hydrophilic gel.

6. The apparatus of claim 1 wherein the agent comprises a coating applied to an interior surface of the tube comprising a biocompatible supporting matrix with a mitosis-inhibiting agent dispersed therein for sustained release from the matrix into a central lumen of the tube.

7. The apparatus of claim 5 wherein the agent is selected from the group consisting of paclatexel, sirolimus, taxol and methotrexate.
8. The apparatus of claim 3 wherein the light source is at least one light emitting diode or light emitting plastic and a light reflective surface is provided adjacent the diode for reflecting light from the diode into the tube.

9. The apparatus of claim 8 wherein a plurality of diodes are provided adjacent the tube and the light reflective casing is positioned for enclosing the diodes and the tube therewithin.

10. The apparatus of claim 3 wherein the light source is removably connected to the tube and includes a reflector for directing light from the light source into the tube.

11. The apparatus of claim 3 wherein the source of light energy is a phosphorescent substance that produces visible light through a photogenetic chemical reaction.

12. The apparatus of claim 3 wherein the source of light comprises a phosphorescent substance that is optically coupled to the tube for directing light energy into the lumen of the tube.

13. The apparatus of claim 11 wherein a light reflector is provided proximate the light source for directing the light produced thereby into the tube.

14. A vascular graft for an animal or human patient comprising, a tube having a pair of ends adapted to be grafted to a blood vessel of the patient for circulating the patient's blood therethrough, a cell-division inhibiting agent on an inside surface of the tube for being released into the lumen of the tube and a light-emitting article outside of the tube for transmitting light energy onto the tube, and at least a portion of the tube is formed from material that allows the transmission of light energy from the light-emitting article into the lumen of the tube for irradiating cells of the patient and cell-division of the irradiated cells is inhibited by said agent so as to reduce or eliminate one or more of the symptoms of graft intimal hyperplasia.
15. The vascular graft of claim 14 wherein the light emitting article is constructed to expose the lumen of the tube to light energy within the range of about 300-800 nm.

16. The vascular graft of claim 14 wherein the agent is selected from the group consisting of paclitaxel, sirolimus, taxol and methotrexate.

17. A vascular graft for an animal or human patient comprising, a tube having a pair of ends adapted to be grafted to a blood vessel of the patient for circulating the patient’s blood therethrough and a drug eluting coating applied to the interior of the tube and the drug is an agent for inhibiting cell division that is dispersed in the coating in an amount of about 0.5% to about 65% by weight so as to expose the interior of the tube to the agent for reducing or eliminating one or more of the symptoms of graft intimal hyperplasia.

18. The apparatus of claim 17 wherein the cell-division inhibiting agent comprises an anticarcinogen.

19. The apparatus of claim 17 wherein a source of light energy is connected to the tube to simultaneously direct light onto the tube and the tube is transparent to the light energy applied thereto such that the light energy passes through the tube into the lumen thereof to be able during use to expose mobile proliferating cells therein to said light energy and thereby act synergistically by killing off cells that are weakened by the cell-growth inhibiting substance.

20. The apparatus of claim 18 wherein the agent is selected from paclitaxel, sirolimus, taxol and methotrexate.

21. The apparatus of claim 17 wherein the drug eluting coating is selected from a plastic resin, an elastomer and a hydrophilic gel.
22. A vascular graft for an animal or human patient comprising, a tube having a pair of ends adapted to be grafted to a blood vessel of the patient for circulating the patient's blood therethrough, a light source for inhibiting cell division operatively connected to the tube so as to expose the interior of the tube to light for reducing or eliminating one or more of the symptoms of graft intimal hyperplasia, the light source is at least one light emitting diode, a light emitting plastic or phosphorescent substance and a light reflective surface is provided adjacent thereto for reflecting light from the source into the tube.

23. The apparatus of claim 22 wherein the light source is a plurality of diodes or light emitting plastic that is provided adjacent the tube and the reflective surface is a light reflective casing enclosing the diodes and the tube therewithin.

24. The apparatus of claim 22 wherein the light source is removably connected to the tube and includes a reflector for directing light from the light source into the tube.

25. A vascular graft for an animal or human patient comprising, a tube having a pair of ends adapted to be grafted to a blood vessel of the patient for circulating the patient's blood therethrough, an agent for inhibiting cell division operatively connected to the interior of the tube so as to expose the interior of the tube to the cell-division inhibiting agent for reducing or eliminating one or more of the symptoms of graft intimal hyperplasia, a source of light energy is connected to the tube to simultaneously direct light onto the tube and the tube is transparent to the light energy applied thereto such that the light energy passes through the tube into the lumen thereof to be able during use to expose mobile proliferating cells therein to said light energy and thereby act synergistically by killing off cells that are weakened by the cell-growth inhibiting substance.
26. The apparatus of claim 25 wherein the cell-division inhibiting agent comprises an anticarcinogen.

27. The apparatus of claim 25 wherein the source of light energy is cool visible light that is directed onto the tube and the tube is transparent to the light energy applied thereto such that the light energy passes through the tube into the lumen thereof to thereby expose mobile proliferating cells therein to said light energy.

28. The apparatus of claim 25 wherein the agent for inhibiting cell division is selected from paclitaxel, sirolimus, taxol and methotrexate.

29. The apparatus of claim 25 wherein the agent is dispersed in a matrix selected from a plastic resin, an elastomer and a hydrophilic gel that is applied to the tube.

30. A vascular graft for an animal or human patient comprising, a tube having a pair of ends adapted to be grafted to a blood vessel of the patient for circulating the patient's blood therethrough and a cool light source having wavelength between about 300 nm to about 800 nm for inhibiting cell-division operatively connected to the tube so as to expose the interior of the tube to the light for thereby reducing or eliminating one or more of the symptoms of graft intimal hyperplasia.

31. The apparatus of claim 30 wherein the light energy is blue visible light having a wavelength between about 300 nm to about 500 nm directed onto the tube and the tube is transparent to the light energy applied thereto such that the light energy passes through the tube into the lumen thereof to thereby expose mobile proliferating cells therein to said light energy.

32. The apparatus of claim 30 wherein the light energy is red visible light having a wavelength between about 600 nm and about 800 nm.

33. A vascular graft for an animal or human patient comprising, a tube having a pair of ends adapted to be grafted to a blood vessel of the patient for circulating the
patient’s blood therethrough and an agent for inhibiting cell division dispersed in a matrix for eluting the agent that is connected to the tube so as to expose the interior of the tube to the agent for reducing or eliminating one or more of the symptoms of graft intimal hyperplasia and the matrix is selected from; a copolymer of dimethylsiloxane and methyl vinyl siloxane, a copolymer of polyurethane and silicone, silicone rubber, a copolymer of polylactic acid and polyglycolic acid, a polyortho ester, a poly (alpha-hydroxy ester), a polyanhydride, a tyrosine-derived polycarbonate, a polyacrylate, lactide based polydepsipeptide polymer, a poly (L-lactic acid-do-L-aspartic acid), and a lactide based polyethylene glycol.

34. The apparatus of claim 33 wherein the cell-division inhibiting agent comprises an anticarcinogen.

35. The apparatus of claim 33 wherein a source of light energy is connected to the tube and the tube is transparent to the light energy applied thereto such that the light energy passes through the tube into the lumen thereof to thereby expose mobile proliferating cells therein to said light energy for acting synergistically during use by killing off cells that are weakened by the cell-division inhibiting agent.

36. The apparatus of claim 33 wherein the agent is selected from paclitaxel, sirolimus, taxol and methotrexate.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
IPC: A61F 2/06 (2006.01)
USPC: 623/1.42,1.46
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
U.S.: 623/1.42, 1.46

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 6,087,552 A (Gregory) 11 June 2000 (11.06.2000), col. 2, lines 27-29, 44-50, 55-58, 62-65, col. 5, lines 58-67, col. 6, lines 24-67, col. 9, lines 4-9, lines 26-32</td>
<td>14-16</td>
</tr>
<tr>
<td>Y</td>
<td>US 6,273,913 B1 (Wright et al.) 14 August 2001 (14.08.2001) col.s 1-6</td>
<td>3, 8, 10-11</td>
</tr>
</tbody>
</table>

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:
  "A" document defining the general state of the art which is not considered to be of particular relevance
  "E" earlier application or patent published on or after the international filing date
  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (to specified)
  "O" document referring to an oral disclosure, use, exhibition or other means
  "P" document published prior to the international filing date but later than the priority date claimed
  "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
  "&" document member of the same patent family

Date of the actual completion of the international search
29 March 2006 (29.03.2006)

Date of mailing of the international search report
20 APR 2006

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US
Commissioner of Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450
Facsimile No. (571) 273-3201

Authorized officer: Suzette J-Gherri
Telephone No. 571-272-4751